Who is sponsoring NCT02657447?

NCT02657447 is sponsored by Nordic Nanovector.

What condition does NCT02657447 study?

NCT02657447 studies Non-Hodgkin Lymphoma.

What drugs are being tested in NCT02657447?

Interventions: Betalutin with lilotomab dose 1, Betalutin with lilotomab dose 2.

What is the status of NCT02657447?

NCT02657447 is currently WITHDRAWN.

Last reviewed 2019-01-08 · How we verify

A Phase 1, Open Label, Randomized Study to Assess Pharmacokinetics, Biodistribution and Radiation Dosimetry of Lutetium (177Lu) Lilotomab Satetraxetan (Betalutin®) Radioimmunotherapy in Patients With Relapsed Non-Hodgkin Lymphoma

NCT02657447 Phase 1 WITHDRAWN

This study is a phase I, open label, randomized study to assess pharmacokinetics, biodistribution and radiation dosimetry of lutetium (177Lu) lilotomab satetraxetan (Betalutin®) radioimmunotherapy in patients with relapsed non-Hodgkin lymphoma. The study will also investigate the safety, toxicity and efficacy of Betalutin and pre-dosing.

Details

Lead sponsor	Nordic Nanovector
Phase	Phase 1
Status	WITHDRAWN
Start date	2017-12-19
Completion	2020-09

Conditions

Non-Hodgkin Lymphoma

Interventions

Betalutin with lilotomab dose 1
Betalutin with lilotomab dose 2

Primary outcomes

Dosimetry — 3 weeks
Estimation of individual tumour/organ uptake and retention of radioactivity.

Countries

Germany